Nexalin Technology, Inc.: directors' dealings · United States · SEC (Form 4)

About Nexalin Technology, Inc.

Nexalin Technology, Inc. (Nasdaq: NXL) is a U.S.-listed medical device company headquartered in Houston, Texas, United States, and traded on the NASDAQ Capital Market. Originally formed as a Nevada corporation in 2010 and later reorganized into a Delaware company in 2021, Nexalin is focused on non-invasive neurostimulation technologies aimed at mental health and neurological conditions. The company’s core proposition is built around proprietary bioelectronic devices and its Deep Intracranial Frequency Stimulation (DIFS™) platform, which it describes as a drug-free approach designed to influence brain activity without relying on psychotherapy as the primary intervention. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) From an operating standpoint, Nexalin develops and commercializes neurostimulation products positioned for indications such as anxiety, insomnia, and depression, while increasingly broadening its clinical narrative toward traumatic brain injury, PTSD, Alzheimer’s disease, dementia, ADHD, and substance-use disorders. Its product portfolio and messaging have centered on Gen-1 systems as well as newer-generation solutions including Gen-2 SYNC and HALO™, with an emphasis on patient usability, clinical data capture, remote monitoring, and virtual clinic infrastructure that supports research and treatment workflows. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) In competitive terms, Nexalin remains a specialized and relatively early-stage player rather than a scaled commercial medtech platform. Its differentiation rests on intellectual property, peer-reviewed clinical publications, and regulatory engagement with the U.S. FDA. The company seeks to position its DIFS technology as a more evidence-based and deeper-acting alternative to more superficial neurostimulation approaches, and it has highlighted U.S. patent protection in substance-use disorder applications as an important strategic asset. ([nexalin.com](https://nexalin.com/nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation/?utm_source=openai)) Geographically, Nexalin’s principal executive offices are in Houston, Texas, while investor relations and transfer-agent support are managed through New York. The company’s communications also point to international activity, including leadership meetings in both the U.S. and China, suggesting that expansion potential is not limited to the domestic market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai)) Recent developments have been central to the investment case. During 2025 and 2026, Nexalin reported additional positive clinical data in Alzheimer’s disease, published peer-reviewed results across multiple indications, advanced a pivotal trial for HALO™ Clarity, secured USPTO patent coverage for substance-use disorders, and completed phases one through five of its virtual clinic and digital ecosystem. At the same time, the company’s 2025 annual report states that it has incurred significant losses and has substantial doubt about its ability to continue as a going concern, underscoring the importance of capital access and execution risk for investors. ([nexalin.com](https://nexalin.com/nexalin-technology-announces-completion-of-phases-one-through-five-of-its-virtual-clinic-and-digital-ecosystem-for-halo-clinical-research-and-patient-management/?utm_source=openai))